Share on StockTwits

Research analysts at Roth Capital decreased their price target on shares of Kindred Biosciences (NYSE:KIN) to $11.50 in a report released on Thursday. Roth Capital’s price objective would suggest a potential downside of 21.29% from the company’s current price.

Separately, analysts at Craig Hallum initiated coverage on shares of Kindred Biosciences in a research note on Friday, May 23rd. They set a “buy” rating on the stock. Three analysts have rated the stock with a buy rating, Kindred Biosciences has a consensus rating of “Buy” and a consensus price target of $17.58.

Shares of Kindred Biosciences (NYSE:KIN) opened at 14.21 on Thursday. Kindred Biosciences has a 52-week low of $8.75 and a 52-week high of $26.99. The stock has a 50-day moving average of $15.89 and a 200-day moving average of $18.09. The company’s market cap is $280.1 million.

Kindred Biosciences (NYSE:KIN) last released its earnings data on Wednesday, August 13th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $0.07. Analysts expect that Kindred Biosciences will post $-1.75 EPS for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.